PolarityTE jumps on FDA tag for SkinTE

RegenETP,

13/05/2022 16:26

** Tissue-based treatment developer's shares  PTE.O  rise
42% to $0.20
    ** Co says U.S. FDA has granted 'Regenerative Medicine
Advanced Therapy' designation to SkinTE  urn:newsml:reuters.com:*:nPn9YjTg9a
    ** SkinTE is the company's product candidate for people who
require skin regeneration treatment
    ** PolarityTE is now pursuing first of two pivotal studies
on SkinTE needed to support a marketing application for chronic
cutaneous ulcer indication
    ** Including session's moves, stock down ~65% YTD, 

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))